Hanbiao Yang

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 10 EPO patents. Top assignee: Peloton Therapeutics, Inc.. Active years: 2017-2025.

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 6)

Average Co-Inventor Count = 6.2

ph-index = 7

Forward Citations = 81(Granted Patents)

Location History:

San Diego, CA (US) (2023)
Coppell, TX (US) (2017 - 2024)

Company Filing History:

13 out of 18

Peloton Therapeutics, Inc.

patents

Years Active: 2017-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331068 - Compositions and methods for inhibiting CD73 (2025-06-17),

2. RE49948 - Aryl ethers and uses thereof (2024-04-30),

3. 11591355 - CD73 inhibitors and uses thereof (2023-02-28),

4. 10807948 - Aromatic compounds and uses thereof (2020-10-20),

5. 10597366 - Aryl ethers and uses thereof (2020-03-24),

6. 10155726 - Substituted pyridines and uses thereof (2018-12-18),

7. 10144711 - Aryl ethers and uses thereof (2018-12-04),

8. 10040767 - Benzimidazole derivatives and uses thereof (2018-08-07),

9. 9969689 - Aryl ethers and uses thereof (2018-05-15),

10. 9908845 - Aryl ethers and uses thereof (2018-03-06),

11. 9896418 - Aryl ethers and uses thereof (2018-02-20),

12. 9884843 - Cyclic sulfone and sulfoximine analogs and uses thereof (2018-02-06),

13. 9796697 - Tricyclic inhibitors of HIF-2-alpha and uses thereof (2017-10-24),

Title: The Innovative Mind of Hanbiao Yang: A Pathway to Cancer Treatment

Introduction

Hanbiao Yang is an accomplished inventor based in Coppell, TX, known for his significant contributions to the field of biochemistry and cancer treatment. He holds an impressive portfolio of 12 patents, showcasing his dedication to innovation and the advancement of medical therapies.

Latest Patents

Among his most recent and impactful patents are those related to HIF-2α inhibitors and CD73 inhibitors. The patent on HIF-2α inhibitors details methods for developing compounds that effectively treat cancer, demonstrating potent results in various assays and leading to tumor size reduction in mouse models. This innovative work is crucial in the ongoing fight against cancer, paving the way for potential new therapies. The CD73 inhibitors patent includes compounds that modulate CD73 activity, offering therapeutic avenues for diseases associated with this protein. Together, these inventions highlight Hanbiao's commitment to advancing medical science through targeted treatment strategies.

Career Highlights

Hanbiao Yang is a vital part of Peloton Therapeutics, Inc., where he continues to push the boundaries of cancer research and pharmaceutical development. His work at Peloton has significantly impacted the landscape of cancer therapy, aligning with the company's mission of advancing novel treatments for patients.

Collaborations

Throughout his career, Hanbiao has collaborated with talented coworkers, including Paul Wehn and James P. Rizzi. Their collective efforts have fostered a dynamic research environment that thrives on innovation and shared expertise. These collaborations enhance the development of groundbreaking therapies that can transform patient outcomes.

Conclusion

In summary, Hanbiao Yang is a prominent figure in the realm of biochemistry and cancer treatment, with a strong record of patents that contribute to essential medical innovations. His latest work on HIF-2α and CD73 inhibitors reflects a dedication to developing effective therapies, showcasing his role as a leading inventor in the industry. As he continues to work at Peloton Therapeutics, the future of cancer treatment looks promising with the innovations he and his colleagues are bringing to life.